Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;17(4):1378-1392.
doi: 10.1007/s13311-020-00920-8.

Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism

Susanne A Schneider  1 , Baccara Hizli  2 , Roy N Alcalay  3
Affiliations
Review

Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism

Susanne A Schneider et al. Neurotherapeutics. 2020 Oct.

Abstract

In recent years, a precision medicine approach, which customizes medical treatments based on patients' individual profiles and incorporates variability in genes, the environment, and lifestyle, has transformed medical care in numerous medical fields, most notably oncology. Applying a similar approach to Parkinson's disease (PD) may promote the development of disease-modifying agents that could help slow progression or possibly even avert disease development in a subset of at-risk individuals. The urgent need for such trials partially stems from the negative results of clinical trials where interventions treat all PD patients as a single homogenous group. Here, we review the current obstacles towards the development of precision interventions in PD. We also review and discuss the clinical trials that target genetic forms of PD, i.e., GBA-associated and LRRK2-associated PD.

Keywords: GBA; Genetic Parkinson’s disease; LRRK2; SNCA; TORC1 inhibitor; Venglustat; ambroxol; clinical trial; kinase inhibitor; small molecule compounds.

PubMed Disclaimer

Conflict of interest statement

Dr. Alcalay reports receiving consultation fees from Genzyme/Sanofi, Roche, Janssen, and ResTORbio.

Figures

Fig. 1
Fig. 1
Genetic architecture of Parkinson’s disease, modified from [4] and [5], showing the continuum of variants of different effect strengths and allele frequencies. The size of the bubbles roughly corresponds to population allele frequencies. Colors symbolize modes of inheritance: dominant (red), recessive (yellow), risk loci (green). The genetic risks for PD can be roughly divided into three groups (dotted areas; see main text for more details). The group of common low-risk genes (lower right corner) includes more than 90 putative independent genome-wide significant signals identified in a GWAS meta-analysis based on more than 13,000 patients and 95,000 controls [6]. Similar to LRRK2 and SNCA, some mutations in VPS13C and GCH1 are likely causal or confer high risk for PD [6]
Fig. 2
Fig. 2
World map of SNCA-associated Parkinsonism. A total of 140 cases have been reported in the literature. Circles reflect frequency per region. Data and image were retrieved from the MDSGene Website [21]
Fig. 3
Fig. 3
Treatment approaches for GBA-associated PD include the modulation of glycosphingolipid turnover and restoration of enzyme function
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts.
    Dratch L, Azage M, Baldwin A, Johnson K, Paul RA, Bardakjian TM, Michon SC, Amado DA, Baer M, Deik AF, Elman LB, Gonzalez-Alegre P, Guo MH, Hamedani AG, Irwin DJ, Lasker A, Orthmann-Murphy J, Quinn C, Tropea TF, Scherer SS, Ellis CA. Dratch L, et al. J Neurol. 2024 Feb;271(2):733-747. doi: 10.1007/s00415-023-12058-6. Epub 2023 Oct 27. J Neurol. 2024. PMID: 37891417 Free PMC article. Review.
  • What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.
    Crotty GF, Schwarzschild MA. Crotty GF, et al. Neurology. 2022 Aug 16;99(7 Suppl 1):34-41. doi: 10.1212/WNL.0000000000200238. Neurology. 2022. PMID: 35970592 Free PMC article. Review.
  • The epigenetic modification of DNA methylation in neurological diseases.
    Li L, Chen R, Zhang H, Li J, Huang H, Weng J, Tan H, Guo T, Wang M, Xie J. Li L, et al. Front Immunol. 2024 Sep 23;15:1401962. doi: 10.3389/fimmu.2024.1401962. eCollection 2024. Front Immunol. 2024. PMID: 39376563 Free PMC article. Review.
  • Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.
    Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Foroud T, Hall A, Marder KS, Mata IF, Mencacci NE, Nance MA, Schwarzschild MA, Simuni T, Bressman S, Wills AM, Fernandez HH, Litvan I, Lyons KE, Shill HA, Singer C, Tropea TF, Vanegas Arroyave N, Carbonell J, Cruz Vicioso R, Katus L, Quinn JF, Hodges PD, Meng Y, Strom SP, Blauwendraat C, Lohmann K, Casaceli C, Rao SC, Ghosh Galvelis K, Naito A, Beck JC, Alcalay RN. Cook L, et al. Brain. 2024 Aug 1;147(8):2668-2679. doi: 10.1093/brain/awae142. Brain. 2024. PMID: 39074992 Free PMC article.
  • The commercial genetic testing landscape for Parkinson's disease.
    Cook L, Schulze J, Verbrugge J, Beck JC, Marder KS, Saunders-Pullman R, Klein C, Naito A, Alcalay RN; ClinGen Parkinson's Disease Gene Curation Expert Panel and the MDS Task Force for Recommendations for Genetic Testing in Parkinson's Disease; Clinical Genome Resource (ClinGen) Parkinson's Disease Gene Curation Expert Panel Authors; Movement Society Disorder (MDS) Task Force on Recommendations for Clinical Genetic Testing in Parkinson's Disease Authors. Cook L, et al. Parkinsonism Relat Disord. 2021 Nov;92:107-111. doi: 10.1016/j.parkreldis.2021.10.001. Epub 2021 Oct 19. Parkinsonism Relat Disord. 2021. PMID: 34696975 Free PMC article.
See all "Cited by" articles

References

    1. Global, regional, and national burden of Parkinson's disease 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17:939–953. - PMC - PubMed
    1. Abrahams E, President | Personalized Medicine Coalition Personalized Medicine: The Changing Landscape of Health Care; Key Note lecture, The 2nd Biomarker Meeting in Personalized Reproductive Medicine Valencia, Spain [www.comtecmed.com/biomarker/2014/Uploads/Editor/PDF/ppt/Edward%20Abraham...]2014.
    1. Juengst E, McGowan ML, Fishman JR, Settersten RA., Jr From "Personalized" to "Precision" Medicine: The Ethical and Social Implications of Rhetorical Reform in Genomic Medicine. Hastings Cent Rep. 2016;46:21–33. - PMC - PubMed
    1. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–753. - PMC - PubMed
    1. Gasser T. Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review. J Park Dis. 2015;5:209–215. - PMC - PubMed

Publication types

MeSH terms

Substances